Heterologous booster vaccines reduce severity and mortality in COVID-19 during BA.2 and BA.4/BA.5 omicron predominance in Thailand

Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022

(2022) Lamprini Veneti et al.   Eurosurveillance

The T cell immune response against SARS-CoV-2

(2022) Paul Moss   NATURE IMMUNOLOGY

Homologous and Heterologous Covid-19 Booster Vaccinations

(2022) Robert L. Atmar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans

(2022) Florian B. Mayr et al.   NEW ENGLAND JOURNAL OF MEDICINE

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

(2022) Jill M. Ferdinands et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study

(2022) Jing Lian Suah et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

(2022) Tommy Nyberg et al.   LANCET

Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study

(2022) Peter Bager et al.   LANCET INFECTIOUS DISEASES

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron

(2022) Emma K. Accorsi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expert review on global real-world vaccine effectiveness against SARS-CoV-2

(2022) Sunate Chuenkitmongkol et al.   Expert Review of Vaccines

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

(2022) Yunlong Cao et al.   NATURE

Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5

(2022) Nicole P. Hachmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

The recently emerged BA.4 and BA.5 lineages of Omicron and their global health concerns amid the ongoing wave of COVID-19 pandemic – Correspondence

(2022) Ranjan K. Mohapatra et al.   International Journal of Surgery

Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study

(2022) Tarun Bhatnagar et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Hybrid immunity and strategies for COVID-19 vaccination

(2022) David S Hui   LANCET INFECTIOUS DISEASES

Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa

(2022) Nicole Wolter et al.   Nature Communications

Reduction in severity and mortality in COVID-19 patients owing to heterologous third and fourth-dose vaccines during the periods of delta and omicron predominance in Thailand

(2022) Kannikar Intawong et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

(2021) Joana Barros-Martins et al.   NATURE MEDICINE

The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions—Ending the COVID-19 Pandemic

(2021) Alexander Doroshenko   JAMA Network Open

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE